A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Part of paid clinical trials in Los Angeles, California.

Sponsor
Celgene
Study ID
NCT04064060
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Beta-thalassemia
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Luspatercept — DRUG
    Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution

Study Details

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase * Transition Phase is defined as one Enrollment visit * Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol * Follow-up Phase includes: \- 42 Day Safety Follow-up Visit * During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting \- Long-term Post-treatment Follow-up (LTPTFU) Phase * Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or disease related therapies should be collected at the same time schedule Participants transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The ACE-536-LTFU-001 rollover study will be terminated, and relevant participants will discontinue from the study when all participants fulfill 5 years on the study, including treatment and follow-up.

Key Dates

Start date
Aug 12, 2019
Status verified
May 2026
Primary completion
May 12, 2028
Completion
May 12, 2028

Study Design

Enrollment
665 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ACE-536
    Luspatercept will be administered as a subcutaneous (SC) injection to participants by the study staff at the clinical site and administration will be documented in the subject's source record.

Primary Outcome Measure

Adverse Events (AEs) [ Time Frame: From enrollment until at least 42 Day Safety Follow-up Phase ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (12)

FacilityCityStateZIPSite coordinators
Local Institution - 968Los AngelesCalifornia90027-6062-
Local Institution - 971OaklandCalifornia94609-
Local Institution - 978StanfordCalifornia94305-
Local Institution - 975TampaFlorida33612-
Local Institution - 970ChicagoIllinois60611-
Local Institution - 973BostonMassachusetts02115-
Local Institution - 961DetroitMichigan48201-
Local Institution - 969New YorkNew York10065-
Local Institution - 967ClevelandOhio44195-
Local Institution - 972PhiladelphiaPennsylvania19104-
Vanderbilt - Ingram Cancer CenterNashvilleTennessee37232-5505-
The University of Texas - MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Los Angeles, CA

By research site
Local Institution - 968· Los Angeles, CALocal Institution - 971· Oakland, CALocal Institution - 978· Stanford, CALocal Institution - 975· Tampa, FLLocal Institution - 970· Chicago, ILLocal Institution - 973· Boston, MA

Related Studies